Suchergebnisse - "Chau, Ian"

PubPharm (39)

1

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

enthalten in: BMC cancer | 2023

von Lau, D. | Fong, C. | Arouri, F. | +14

2

Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer

enthalten in: Expert opinion on drug safety | 2022

von Lau, D. | Mencel, J. | Chau, I.

3

Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma : propensity score-matched study

enthalten in: BJS open | 2022

von Moussa, O. | Bhogal, R. | Malietzis, G. | +10

4

Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage

enthalten in: Nature communications | 2021

von Carotenuto, P. | Amato, F. | Lampis, A. | +35

5

NET-02 trial protocol : a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)

enthalten in: BMJ open | 2020

von Craig, Z. | Swain, J. | Batman, E. | +16

6

ACORN : Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK

enthalten in: Clinical colorectal cancer | 2019

von Khakoo, S. | Chau, I. | Pedley, I. | +10

7

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer : Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

enthalten in: Clinical colorectal cancer | 2019

von Riechelmann, R. | Srimuninnimit, V. | Bordonaro, R. | +19

8

Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer : A Systematic Review and Patient-Level Meta-Analysis

enthalten in: Journal of the National Cancer Institute | 2019

von Janssen, Q. | Buettner, S. | Suker, M. | +45

9

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL) : a double-blind, randomised, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Fuchs, C. | Shitara, K. | Di Bartolomeo, M. | +122

CommentIn: Lancet Oncol. 2019 Mar;20(3):323-324. - PMID 30718071

10

Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies : Large Single-Center Experience

enthalten in: Clinical colorectal cancer | 2019

von Khan, K. | Rane, J. | Cunningham, D. | +9